Related MeSH Hierarchy (4)
Diseases [C] » Infections [C01] » Communicable Diseases » Blood-Borne Infections » Hepatitis C
Diseases [C] » Infections [C01] » Virus Diseases » Hepatitis, Viral, Human » Hepatitis C
Diseases [C] » Infections [C01] » Virus Diseases » RNA Virus Infections » Flaviviridae Infections » Hepatitis C
Diseases [C] » Digestive System Diseases [C06] » Liver Diseases » Hepatitis » Hepatitis, Viral, Human » Hepatitis C
Description
INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. MeSH
Hierarchy View
Subtype Terms (1)
Hepatitis C, Chronic
248 drugs (103 approved, 145 experimental)
Phase 4 Indicated Drugs (51)
Phase 3 Indicated Drugs (28)
Phase 2 Indicated Drugs (51)
Phase 1 Indicated Drugs (67)
Other Experimental Indicated Drugs (19)
Organization Involved with Phase 4 Indications (255)
Ahvaz Jundishapur University of Medical Sciences
Alexander von Humboldt Association
American Research Corporation (ARC)
Badalona Hospital Germans Trias i Pujol
Baqiyatallah Medical Sciences University
California HIV/AIDS Research Program
Canadian Institutes of Health Research (CIHR)
Center For Hepatitis C, Atlanta, GA
Chronic Liver Disease Foundation
City of Hope National Medical Center
Clinical Pharmacology of Miami
Community Research Initiative of New England
Federal University of Health Science of Porto Alegre
Federal University of Rio de Janeiro
Fundacio Lluita Contra la SIDA
Hamadan University of Medical Science
Hannover Clinical Trial Center GmbH
Hospital Federal de Bonsucesso
Hospital Universitario Fundación Alcorcón
Hospital Universitario San Cecilio
Humanity & Health Research Centre
Icahn School of Medicine at Mount Sinai
International Society for Infectious Diseases
Iranian Blood Transfusion Research Center
King Faisal Specialist Hospital
Mater Misericordiae University Hospital
Medical University of South Carolina
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Drug Abuse (NIDA)
New York Presbyterian Hospital
Oregon Health and Science University
Orlando Clinical Research Center
PEI Provincial Correction Centre
People's Liberation Army of China
Pontificia Universidad Catolica de Chile
Principal SIMS/Services hospital lahore
Research Foundation for Mental Hygiene, Inc.
SC Liver Research Consortium, LLC
Services Institute of Medical Sciences, Pakistan
Shahid Beheshti University of Medical Sciences
Sociedad Andaluza de Enfermedades Infecciosas
Southern California Research Center
State University of New York, Syracuse
Taichung Veterans General Hospital
The University of Texas, Dallas
Tropical Diseases Hospital, Ho Chi Minh City
University of California, Los Angeles
University of California, San Francisco
University of Colorado, Denver
University of Medicine and Dentistry of New Jersey
University of Roma La Sapienza
University of Southern California
University of Texas at Houston
University of Texas, San Antonio
Virginia Commonwealth University
Western Hospital, Footscray, Victoria. Australia
Wilhelminenspital der Stadt Wien
Yassin Abdelghaffar Charity Center for Liver Disease and Research
Yassin Abdel Ghaffar Charity Center for Liver Disease and Research
Organization Involved with Phase 3 Indications (158)
Ascletis Pharmaceuticals Co., Ltd.
Associazione Italiana per la Ricerca sul Cancro
Azienda Ospedaliera S Giovanni Battista
Beijing Kawin Technology Share-Holding Co., Ltd.
Casa Sollievo della Sofferenza IRCCS
CIHR Canadian HIV Trials Network
Clinique Medicale L'Actuel, Que
Drugs for Neglected Diseases Initiative
Federal University of Rio Grande do Sul
French National Agency for Research on AIDS and Viral Hepatitis
Hospital Universitario Virgen Macarena
Institute Of Cardiology & Internal Diseases, Kazakhstan
Istituto Clinico Humanitas - Rozzano (MI), Italy
Kazan State Medical University
Kermanshah University of Medical Sciences
Kirov Military Medical Academy
LLC Medical Company Hepatolog, Samara, Russia
Minnesota Veterans Medical Research and Education Foundation
MTI Medical Private Limited, Pakistan
M V Hospital & Research Center, Lucknow
Nanjing Sanhome Pharmaceutical, Co., Ltd.
National Center for Research Resources (NCRR)
National Cheng Kung University
Regional State Healthcare Institution Smolensk Regional Clinical Hospital
RojanPharma Pharmaceutical Company
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Smolensk State Medical Academy
Society of Friends of Liver Patients in the Arab World (SLPAW)
Southern California Institute for Research and Education
St. Petersburg City Health Department
Sunshine Lake Pharma Co., Ltd.
Taipei Veteran General hospital
TCM Biotech International Corp.
The Egyptian Company for Blood Transfusion Services
Translational Research Informatics Center, Kobe, Hyogo, Japan
Universidad Autonoma de Barcelona
University of British Columbia
University of California, Irvine
University of Modena and Reggio Emilia
University of Naples Frederico II
University of North Carolina at Chapel Hill
V.I. Razumovsky, Healthcare Committee at the Administration of Saratov City Municipal District
Vita-Salute University of Milano. Italy
Xiamen Amoytop Biotech Co., Ltd.
Organization Involved with Phase 2 Indications (134)
Antipodean Pharmaceuticals, Inc.
Atlanta Gastroenterology Associates
Azienda Ospedaliera Universitaria Policlinico
Cantonal Hospital of St. Gallen
Cell Therapy And Technology, S.a. De C.v.
Chao Family Comprehensive Cancer Center
Daiwa Pharmaceutical Corporation
Florida Center for Gastroenterology
Fondazione Italiana Diabete Onlus
Fundacion de Investgacion de Diego
German Center for Infection Research
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Institut National de la Santé Et de la Recherche Médicale, France
Nashville Medical Research Institute
National Center for Complementary and Integrative Health (NCCIH)
National Center for Global Health and Medicine
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Nursing Research (NINR)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
New England Research Institutes
Office of Dietary Supplements (ODS)
Razi Vaccine and Serum Research Institute
Russian Academy of Medical Sciences
Shanghai Sundise Traditional Chinese Medicine Co., Ltd.
TaiGen Biotechnology Co., Ltd.
Organization Involved with Phase 1 Indications (46)
Organization Involved with Other Experimental Indications (28)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
